A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination with Pazopanib for Refractory Soft Tissue Sarcoma
The purpose of this study is to compare the effects, good and/or bad between gembitabine given by itself and gemcitabine combined with the study drug, pazopanib. We currently do not know which of these two treatments is better. The drug gemcitabine will be given as an infusion and the drug pazopanib will be taken as a pill each day.
This randomized trial studies how well gemcitabine works with or without pazopanib in treating patients with soft tissue sarcoma.
Soft tissue sarcoma
*Adults with metastatic soft tissue sarcoma
*Patients must have already received at least one, but not more than three previous treatments for metastatic soft tissue sarcoma
*Patients should not have been previously treated with gemcitabine, pazopanib, sorafenib, or bevacizumab
*Other eligibility criteria will apply
18 - 120
Healthy Volunteers Needed
Duration of Participation
Patients will receive the study drugs until it is no longer benefiting them. After patients stop receiving drug, they will be followed every 3 months to see how they're doing.
Knight Clinical Trials Information Line